Tonix Pharmaceuticals Names CEO Seth Lederman Interim Chief Medical Officer

What Happened
Tonix Pharmaceuticals Holding Corp. filed a Form 8‑K on August 18, 2026 (Items 5.02 and 8.01) announcing that Dr. Seth Lederman, the company’s President, Chief Executive Officer and Chairman, has been appointed Interim Chief Medical Officer. Dr. Lederman, age 69, has served as President, CEO and Chairman since October 2011 and will continue in those roles while taking on interim CMO responsibilities.

Key Details

• Appointment date: August 18, 2026 (reported on Form 8‑K).
• Appointee: Dr. Seth Lederman, age 69; will serve as Interim Chief Medical Officer in addition to President, CEO and Chairman.
• Tenure: Dr. Lederman has been President, CEO and Chairman since October 2011.
• Disclosures: Company stated there are no arrangements or understandings related to the appointment and no family relationships between Dr. Lederman and any other director or executive officer. The appointment was also announced publicly the same day.

Why It Matters
For investors, this is a leadership consolidation: the CEO is temporarily taking on the medical leadership role, which may affect oversight of clinical development and regulatory interactions. The filing is informational (Items 5.02 and 8.01) and does not disclose changes to compensation, the duration of the interim appointment, or other material terms. Investors tracking Tonix’s clinical programs and corporate governance should note the change and watch for any future updates about a permanent CMO or additional organizational changes.